The study is designed as a phase 3, randomized, double-blind trial comparing ersodetug to a placebo. Participants in the study have tumors that cause too much insulin to be released, resulting in dangerously low blood sugar levels that haven’t responded well to typical treatments. These individuals experience multiple episodes of severe hypoglycemia weekly, sometimes requiring assistance from others due to altered mental or physical status.

During the study, participants will receive either ersodetug or placebo while continuing their standard care treatments. Researchers will monitor how frequently participants experience low blood sugar events and how severe these events are. The study will track changes in hypoglycemic episodes and measure blood glucose levels through regular testing to determine if ersodetug helps reduce the frequency and severity of low blood sugar episodes.